Literature DB >> 11393418

Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma.

M Hashimoto1, T Fujishima, H Tanaka, H Kon, T Saikai, A Suzuki, M Nakatsugawa, S Abe.   

Abstract

Recently, various forms of Churg-Strauss syndrome (CSS) have been reported in association with the use of leukotriene receptor antagonists. A 53-year-old woman with a 5-year history of asthma associated with chronic sinusitis presented mononeuropathy, hypereosinophilia, and positive P-ANCA in October 1999. She had been treated with pranlukast (450 mg/day) and beclomethasone dipropionate (BDP) at a dose of 1,200 microg/day which had gradually been tapered to 800 microg/day over the previous 17 months. She was found to have CSS, and 60 mg/day of prednisolone was administered instead of pranlukast, resulting in an improvement of her symptoms and eosinophilia. Later, we confirmed that serum P-ANCA had been positive before the pranlukast treatment, but CSS vasculitis had not appeared at that time. We speculated that an underlying incomplete form of CSS was being masked in this case and that the reduction of inhaled corticosteroid might have been responsible for the unmasking of CSS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393418     DOI: 10.2169/internalmedicine.40.432

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.

Authors:  Junsuke Shimbo; Osamu Onodera; Keiko Tanaka; Shoji Tsuji
Journal:  Clin Rheumatol       Date:  2004-12-02       Impact factor: 2.980

2.  Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast.

Authors:  Toru Watanabe; Yasufumi Iinuma; Shin-ichi Naito; Koju Nitta
Journal:  Eur J Pediatr       Date:  2006-08-17       Impact factor: 3.183

Review 3.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Churg-Strauss syndrome (CSS) in a patient receiving pranlukast.

Authors:  Shigeto Kobayashi; Shyugo Ishizuka; Naoto Tamura; Makiyo Takaya; Kazuhiko Kaneda; Hiroshi Hashimoto
Journal:  Clin Rheumatol       Date:  2003-11-04       Impact factor: 2.980

Review 5.  Pranlukast: a review of its use in the management of asthma.

Authors:  Susan J Keam; Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?

Authors:  Deanna L McDanel; Barbara A Muller
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.